Stock Events

Stock Events

Arcutis Biotherapeutics 

$23.90
133
+$0.24+1.01% Friday 20:00
+$0.50+2.09%Friday 23:51After hours

Statistics

Day High
23.9
Day Low
23.88
52W High
31.77
52W Low
16.21
Volume
53,738
Avg. Volume
-
Mkt Cap
3B
P/E Ratio
-
Dividend Yield
-
Dividend
-

Upcoming

Earnings

29OctExpected
Q4 2024
Q1 2025
Q2 2025
Q3 2025
Q1 2026
Q2 2026
Next
-0.26
-0.11
0.03
0.17
Expected EPS
0.175
Actual EPS
N/A

Financials

-4.29%Profit Margin
Unprofitable
2020
2021
2022
2023
2024
2025
376.07MRevenue
-16.14MNet Income

Analyst Ratings

38.67Average Price Target
The highest estimate is 40.00.
From 3 ratings within the last 6 months. This is not an investment recommendation.
Buy
100%
Hold
0%
Sell
0%

People Also Follow

This list is based on the watchlists of people on Stock Events who follow ARQT. It's not an investment recommendation.
NVIDIA
27
NVDA
Amazon
22
AMZN
Apple
20
AAPL
Microsoft
20
MSFT

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Abbvie
ABBV
Mkt Cap451.46B
AbbVie competes in the dermatology space with treatments like Skyrizi and Rinvoq, which can be direct competitors to Arcutis' dermatological products.
AMGEN
AMGN
Mkt Cap233.78B
Amgen has a strong presence in the treatment of psoriasis and other inflammatory diseases, directly competing with Arcutis' pipeline.
Johnson & Johnson
JNJ
Mkt Cap645.95B
Johnson & Johnson, through its Janssen Pharmaceuticals division, offers products like Stelara and Tremfya, competing in the psoriasis and dermatology market.
Pfizer
PFE
Mkt Cap159.36B
Pfizer has a portfolio of drugs for inflammatory conditions and dermatology, including Xeljanz, which competes in similar therapeutic areas as Arcutis.
GSK
GSK
Mkt Cap101.78B
GlaxoSmithKline has a focus on dermatological conditions, including treatments for skin diseases, positioning it as a competitor.
Novartis
NVS
Mkt Cap292.35B
Novartis offers Cosentyx, a direct competitor in the psoriasis treatment market, challenging Arcutis' product offerings.
Merck
MRK
Mkt Cap366B
Merck has a diversified portfolio that includes treatments for inflammatory diseases, potentially competing with Arcutis in certain therapeutic areas.
Bristol-Myers Squibb
BMY
Mkt Cap136B
Bristol Myers Squibb, with its range of anti-inflammatory and dermatology drugs, competes in the same space as Arcutis.
Regeneron Pharmaceuticals
REGN
Mkt Cap81.77B
Regeneron Pharmaceuticals, known for Dupixent, competes in the dermatology and inflammatory disease market, directly challenging Arcutis' products.
Journey Medical
DERM
Mkt Cap210.84M
Journey Medical Corporation (formerly Dermira), focuses on dermatological conditions, making it a direct competitor in the dermatology space.

About

Arcutis Biotherapeutics Inc is a commercial-stage biopharmaceutical company focused on developing and commercializing treatments for dermatological diseases with high unmet medical needs. Its current portfolio is comprised of differentiated topical and systemic treatments with potential to treat immune-mediated dermatological diseases and conditions. The company's product candidate ZORYVE roflumilast cream, has completed pivotal Phase 3 clinical trials in plaque psoriasis, demonstrating symptomatic improvement and favorable tolerability in this population. The Company has one reportable segment relating to the development and commercialization of treatments for dermatological diseases.
Show more...
CEO
Todd Franklin Watanabe
Employees
354
Country
United States
ISIN
US03969K1088

Listings

BOATS
BOATS
ARQT.BOATS
XNAS
US
ARQT

0 Comments

Share your thoughts

FAQ

What is Arcutis Biotherapeutics stock price today?▼
The current price of ARQT is $23.90 USD — it has increased by +1.01% in the past 24 hours. Watch Arcutis Biotherapeutics stock price performance more closely on the chart.
What is Arcutis Biotherapeutics stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on XNAS exchange Arcutis Biotherapeutics stocks are traded under the ticker ARQT.
Is Arcutis Biotherapeutics stock price growing?▼
ARQT stock has risen by +0.5% compared to the previous week, the month change is a -11.81% fall, over the last year Arcutis Biotherapeutics has showed a +39.36% increase.
What is Arcutis Biotherapeutics market cap?▼
Today Arcutis Biotherapeutics has the market capitalization of 3B
When is the next Arcutis Biotherapeutics earnings date?▼
Arcutis Biotherapeutics is going to release the next earnings report on October 29, 2026.
What were Arcutis Biotherapeutics earnings last quarter?▼
ARQT earnings for the last quarter are 0.11 USD per share, whereas the estimation was 0.06 USD resulting in a +99.73% surprise. The estimated earnings for the next quarter are N/A USD per share.
What is Arcutis Biotherapeutics revenue for the last year?▼
Arcutis Biotherapeutics revenue for the last year amounts to 376.07M USD.
What is Arcutis Biotherapeutics net income for the last year?▼
ARQT net income for the last year is -16.14M USD.
How many employees does Arcutis Biotherapeutics have?▼
As of September 05, 2026, the company has 354 employees.
In which sector is Arcutis Biotherapeutics located?▼
Arcutis Biotherapeutics operates in the Health & Wellness sector.
When did Arcutis Biotherapeutics complete a stock split?▼
Arcutis Biotherapeutics has not had any recent stock splits.
Where is Arcutis Biotherapeutics headquartered?▼
Arcutis Biotherapeutics is headquartered in WESTLAKE VILLAGE, United States.